
How The IRS Decides To Audit You: A Tax Expert Explains
How does the IRS decide which tax returns to audit? In this Q&A series, a former IRS lawyer and ... More current law-school professor explains.
This is the second part of my two-part Q&A with a tax-law expert, professor, and former IRS lawyer. The first part is How The IRS Picks Tax Returns To Audit: A Tax-Law Expert Explains.
'April is the cruelest month' wrote the poet T.S. Eliot—and for taxpayers in the US, that may often be true. The filing deadline for federal tax returns is coming up on April 15. While nobody really likes doing tax-return homework for the IRS, it's safe to say that IRS audits and other forms of unwanted IRS attention are even more unpleasant, making diligence with your tax return a wise course.
For expert insights into how the IRS decides which tax returns to audit and how to prepare for an audit if it happens, I turned to tax expert Professor Bryan Camp. He is a professor at Texas Tech School of Law, a former staff member of the IRS Office of Chief Counsel, and a longtime tax attorney. Between teaching, doing academic research, and playing the fiddle at bluegrass jams, he kindly took time amid his busy schedule to answer my questions with his inside knowledge and personal flair.
In the first part of this Q&A, Professor Camp explained how the IRS selects which tax returns to audit, different types of audits, and how to handle IRS requests. In the second part, presented below, he explains more about how to avoid getting audited by the IRS, what to do if you are audited, tax-return areas that are likely to trigger an audit, and whether someone at the IRS can intentionally select you for an audit or release your tax information.
The biggest way to reduce the chance of any unpleasant interaction with the IRS is to be sure your tax return is consistent with any information returns submitted to the IRS about you, such as a Form 1099 or Form W-2.
When those returns are incorrect, you basically have three choices: (a) suck it up and report consistently with the incorrect information return; (b) attach to your return an explanation for why the information return is incorrect, or (c) make the correct return and then keep all your records because if the discrepancy is large enough you will indeed get a 'love letter' from the IRS asking about it, and you will generally only have a very short timeframe to respond.
Let me give you an example from my own experience. When my grandma died, she left her house to her three grandkids: my two sisters and me. We sold the house. The Title Company then sent the IRS a 1099 reporting that it had paid the ENTIRE sales proceeds to me. That 1099 was wrong for two reasons. First, I split the proceeds with my sisters.
More importantly, the proceeds were excluded from gross income by Internal Revenue Code Section 102 (which allows inheritances to be excluded from income). Pissed, I (properly) did not report any of that money. But you see how the IRS computers thought I had underreported income when they compared the 1099s with my tax return.
But I did not get audited. Instead I received what the IRS calls a 'compliance check.' About two years later I got a love letter (called a CP2000 notice) from the IRS telling me it believed I had overlooked some income I should have reported, and it gave me 30 days to explain why I should have not reported it. Since I was expecting that, I was prepared to respond and so that got cleared up.
Notice two points: (1) it took the IRS systems about two years to catch the discrepancy and ask me about it; (2) I had only 30 days to respond. If I had missed that deadline, then the IRS would have assessed a deficiency, and I would have had a much more difficult time working it out.
First, low incomes. You can look at the IRS Data books for details. Basically, Congress is very concerned that low-income taxpayers are cheating by improperly claiming tax credits such as the Earned Income Tax Credit.
Second, very high incomes. They get reviewed more because their errors cost the government a lot more lost revenue. For example, some large corporations are under continuous examination. In addition, very-high-income taxpayers are more likely to participate in the type of tax-shelter transactions that the IRS targets.
Third, self-employed taxpayers who report income on Schedule C may be more likely to be selected for audit. That is because while the IRS computer matching programs do a great job at spotting potential unreported income, they cannot spot erroneous deductions. So, again, if you report a very large loss on Schedule C and you use that loss to offset your decent wage income, that may trigger a higher DIF score (see the first part of this Q&A).
Yes. But that does not mean the IRS computer systems are shut down and, as I explained earlier, everyone's return is 'looked at' by the IRS computers. The IRS computers will attempt to correct perceived errors in returns by sending out notices like the CP2000 and then propose assessments if the taxpayer does not respond in a timely manner. Those actions are not audits. But they are still unpleasant experiences, even when you are correct.
The IRS almost never does a tip-to-toe audit. Almost always the IRS is looking into a particular issue or set of issues. So you want to be sure you know what the IRS is concerned about. You want to be sure to ask the IRS Revenue Agent what information they need and then give them that information—but ONLY that information.
If the IRS needs more, let them ask for it. You want to avoid letting them come to your home or business, so being cooperative and offering to bring the information to them is generally the best way to respond.
However, if you are worried about being criminally prosecuted, then you want to take the opposite approach and not volunteer information you think could help convict you of a crime. We call these 'eggshell' audits because while it starts out civil, you are walking on eggshells trying to avoid criminal investigation. Don't walk alone. There are many law firms that specialize in these kinds of audits.
Oh yes! If the auditor comes to believe that the taxpayer engaged in fraudulent behavior, the auditor must stop the audit and refer the matter to Criminal Investigation (CI). If CI decides not to work the case, the auditor can resume the audit.
Meanwhile, the auditor is prohibited from contacting the taxpayer during the time CI does its investigation. So if you are being audited and, suddenly, you are totally unable to communicate with your auditor, that's a baaaaaad sign. The eggshells are breaking.
As many years as are necessary to resolve the audit issues. For example, if the audit is about whether you properly reported income from the sale of property, the Revenue Agent is entitled to ask for all your property records back to the time you bought it to establish the proper basis. For a recent Tax Court case where the taxpayer was unable to establish basis on his rental property and therefore was not allowed a depreciation deduction, see Smith v. Commissioner, T.C. Memo. 2025-24 (March 24, 2025).
Another example is if you are claiming tax benefits in the audit year from stuff you did in a prior year; the Revenue Agent is entitled to look at that prior year to see if you did that right. Even though that prior year is not under audit, understanding what happened there may be necessary to resolve the year that is under audit.
As a practical matter, however, IRS employees rarely go beyond the year they are examining.
Training and structure. Informally this is called 'UNAX' for 'Unauthorized Access.'
Training: Employees learn that Congress wrote a statute that makes this behavior a crime. They learn they can go to prison. They also learn that they can be fired.
Structure: Employees have no ability to select a taxpayer for audit. As explained in Part 1 of this Q&A interview, all audit decisions must be made through the proper channels of authority.
And employees who identify a taxpayer for audit are not permitted to conduct the audit. So if a Revenue Agent auditing my tax return comes to believe that I am in cahoots with Joe and recommends opening an examination on Joe, then that recommendation must be approved by a series of IRS supervisors. If approved, Joe's audit must be done by another Revenue Agent. And my Revenue Agent cannot access that information because doing so would be UNAX.
IRS employees are incredibly cautious about accessing information not directly relevant to their jobs. That sometimes interferes with their ability to conduct a thorough audit, because in their mind the risks of UNAX outweigh the benefit to their examination. IRS employees are not evaluated on how many lost tax dollars they uncover. They are instead evaluated on how well they process their workload. That is one reason for cooperating. You help them 'git-er-done.'
Training and consequences. All IRS employees are trained not only that they must keep information confidential but also that they are not even allowed to look at any taxpayer's information unless they are working on that taxpayer's case (either in examination or in collections at the IRS).
To enforce these prohibitions, Congress wrote a statute in 1998 that creates what we call the '10 Deadly Sins.' Professor Keith Fogg wrote an excellent article about that statute, which provides that any IRS employee who improperly discloses taxpayer information may (and sometimes must) be fired.
Congress also wrote another statute on the unauthorized inspection or disclosure of tax returns or return information. That permits the taxpayer to sue the government and recover, at a minimum, $1,000 per improper disclosure Thus, if the improper disclosure goes out on a social media post that receives 1,000 hits, that's 1,000 improper disclosures.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
7 hours ago
- Yahoo
How Much Is Pope Leo XIV's Social Security Check?
Pope Leo XIV, born Robert Francis Prevost in Chicago, is making history as the first American and first Augustinian Pope. His background has already caused plenty of excitement, and lots of questions, including whether or not he gets a Social Security check. Consider This: Read Next: It makes sense to wonder, being as he is, technically, an American citizen. The short answer is no, but the full picture raises some interesting questions about citizenship, religious life and how benefits are determined. There's no direct paycheck waiting for the pope. Instead, the Vatican covers everything including housing, food, healthcare, travel and protection. That's not unique to Pope Leo XIV; it's standard for the job. Technically, he could receive a monthly stipend from the Vatican, rumored to be around $33,000, according to Fortune, but previous popes, like Pope Francis, have turned it down. As a member of the Augustinian Order, which requires a vow of poverty, Pope Leo may follow this precedent. This affects eligibility for Social Security, which depends on having worked in jobs that paid into the system, typically at least 40 credits (around 10 years of work.) As Pope Leo spent much of his adult life in Peru as a missionary and bishop, later taking on high-level roles in Rome, it's unclear whether he worked long enough in the States to qualify. Even if he did, it's hard to imagine him claiming benefits while serving as Pope. Financial support from the Vatican makes Social Security irrelevant in his case. Check Out: Here's where things get trickier. Pope Leo XIV still holds U.S. citizenship. That means he's technically on the hook for U.S. taxes, even while living in Vatican City, as under U.S. law, citizens are taxed on their worldwide income, no matter where they live. But religious vows may change the equation. As a member of a religious order, the Pope may be exempt from some tax requirements — especially if he's assigned any income directly to the order. Still, the IRS could take an interest in the value of non-cash benefits like lodging and transportation, which are often taxable under U.S. rules. There's no public record confirming whether Pope Leo XIV receives a Social Security check, but based on everything known about his life, it's highly unlikely. As a member of a religious order who took a vow of poverty, he likely didn't earn the work credits required for benefits. Even if he technically qualified, any earnings would have been assigned to the order, and his role as Pope comes with full support from the Church. So, while the question is fair to ask, the most reasonable answer is: No, Pope Leo XIV almost certainly isn't getting a check from the Social Security Administration. More From GOBankingRates Warren Buffett: 10 Things Poor People Waste Money On The 5 Car Brands Named the Least Reliable of 2025 This article originally appeared on How Much Is Pope Leo XIV's Social Security Check? Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
7 hours ago
- Yahoo
Immunic Announces Completion of Enrollment for Both Phase 3 ENSURE Trials in Relapsing MS and Presents Additional Data Underlining Positive Outcome of Phase 2 CALLIPER Trial in Progressive MS
– Enrollment Completed for Both Phase 3 ENSURE Trials of Vidofludimus Calcium in Relapsing Multiple Sclerosis; Top-Line Data Expected End of 2026 – – Additional Data from Phase 2 CALLIPER Trial in Progressive Multiple Sclerosis Further Supports the Recently Released Positive Top-Line Results and Further Underlines Vidofludimus Calcium's Neuroprotective Potential – – New CALLIPER Data Regarding Time to 24-Week Confirmed Disability Worsening Shows Substantial and Medically Relevant Reductions for Vidofludimus Calcium Over Placebo in the Overall Study Population and Major Disease Subtypes – NEW YORK, June 5, 2025 /PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammatory and autoimmune diseases, announced the completion of enrollment for both phase 3 ENSURE trials of lead asset, nuclear receptor-related 1 (Nurr1) activator, vidofludimus calcium (IMU-838), in patients with relapsing multiple sclerosis and additional phase 2 CALLIPER trial data in patients with progressive multiple sclerosis underlining the recently released positive top-line results. Enrollment Completed for Both Phase 3 ENSURE Trials in Relapsing Multiple Sclerosis (RMS) The ENSURE program comprises two identical multicenter, randomized, double-blind phase 3 trials designed to evaluate the efficacy, safety and tolerability of vidofludimus calcium versus placebo in RMS patients. Each of the trials, titled ENSURE-1 and ENSURE-2, enrolled adult patients with active RMS at more than 100 sites in 15 countries, including the United States, India and countries in the Middle East and North Africa (MENA) region, Latin America, and Central and Eastern Europe. In total, 1,121 patients in ENSURE-1 and 1,100 patients in ENSURE-2 have been randomized in a double-blinded fashion to either 30 mg daily doses of vidofludimus calcium or placebo. The primary endpoint for both trials is time to first relapse up to 72 weeks. Secondary endpoints include time to confirmed disability worsening based on the Expanded Disability Status Scale (EDSS), volume of new T2-lesions, time to sustained clinically relevant changes in cognition, and magnetic resonance imaging (MRI)-based endpoints. "The on-schedule enrollment of the final patients in our phase 3 ENSURE trials of vidofludimus calcium marks another significant milestone for our late-stage MS program, bringing us meaningfully closer to a potential new treatment option for people living with RMS," commented Daniel Vitt, Ph.D., Chief Executive Officer of Immunic. "We anticipate that the drug's unique neuroprotective effects observed to date will also play a crucial role in the ENSURE trials, where confirmed disability worsening serves as an important secondary outcome. If approved, we believe vidofludimus calcium, with its attractive safety and tolerability profile, compelling dual and novel mechanism of action and combination of neuroprotective, anti-inflammatory, and antiviral effects, could potentially transform the oral MS therapy market, offering a unique first-in-class treatment option by addressing the full spectrum of this disease. We eagerly anticipate the top-line data from both ENSURE trials by the end of 2026, which allows for a synchronized readout and a pooled assessment of the confirmed disability worsening secondary endpoint." Werner Gladdines, Chief Development Officer of Immunic, added, "We are extremely proud to have reached this key milestone for our ENSURE program of vidofludimus calcium, right on schedule. Successfully completing enrollment of over 2,200 RMS patients across the twin phase 3 trials represents a major achievement and a true team effort. We extend our sincere thanks to all Immunic colleagues and vendor staff involved in the planning and execution of the ENSURE trials for their dedication to advancing our late-stage clinical program. We are also deeply grateful for the strong support from our clinical investigators, site study teams, and the study participants and their families. We look forward to analyzing the ENSURE top-line data, which we hope will ultimately pave the way for regulatory filings and the ultimate commercialization of vidofludimus calcium in RMS." Additional Data Available from Phase 2 CALLIPER Trial in Progressive Multiple Sclerosis (PMS) Building on the recently released data showing reductions in the relative risk of 24-week confirmed disability worsening (24wCDW) events based on the Expanded Disability Status Scale (EDSS) at the end of the main treatment period, newly available data for the secondary endpoint of time to 24wCDW based on the EDSS further reinforces the neuroprotective potential of vidofludimus calcium. In the overall PMS patient population (n=467), vidofludimus calcium demonstrated a clinically meaningful reduction of the hazard ratio (HR) for 24wCDW by 24% compared to placebo (HR 0.76). Further analyses by disease subtype showed that vidofludimus calcium was associated with a 33% reduction in 24wCDW in the primary progressive multiple sclerosis (PPMS) study population (n=152) compared to placebo (HR 0.67), a 19% reduction in the non-active secondary progressive multiple sclerosis (naSPMS) study population (n=268) compared to placebo (HR 0.81), and a 34% reduction in the active secondary progressive multiple sclerosis (aSPMS) study population (n=47) compared to placebo (HR 0.66). Similarly, consistent with the recent top-line data, further analyses of subpopulations – both with and without inflammatory gadolinium-enhanced lesion activity at baseline, who are largely shown to not benefit from current anti-inflammatory therapies – continued to demonstrate promising results. For the overall population, vidofludimus calcium reduced 24wCDW in patients without evidence of gadolinium-enhancing lesions at baseline by 34% compared to placebo (HR 0.66). Encouraging results were likewise observed for the PPMS (reduction in 24wCDW: 35%; HR 0.65) and naSPMS (reduction in 24wCDW: 30%; HR 0.70) study populations compared to placebo. "Our recently released positive phase 2 CALLIPER trial data in PMS underlined vidofludimus calcium's neuroprotective potential and its ability to slow disease progression in MS patients with or without focal inflammation. We are very excited that additional analyses of time to 24-week confirmed disability worsening further support this potential, highlighting a significant opportunity ahead," stated Dr. Vitt. "The consistent results for 24wCDW between the general CALLIPER population and patients that show no evidence of focal inflammatory disease at baseline, as exemplified by gadolinium-enhancing lesions during MRI, both for the overall study population and for the PPMS and naSPMS subtypes, supports clinically measurable neuroprotective effects of vidofludimus calcium, consistent with its Nurr1 activation mechanism. We believe, because 24wCDW is an acceptable regulatory endpoint to determine clinical benefit in PMS, the suggestive evidence of clinical activity in 24wCDW clearly deserves further investigation in a phase 3 program." About Vidofludimus Calcium (IMU-838)Vidofludimus calcium is an orally administered investigational small molecule drug being developed for chronic inflammatory and autoimmune diseases, currently in late-stage clinical trials for multiple sclerosis (MS). Uniquely, vidofludimus calcium's first-in-class, dual mode of action combines neuroprotective, anti-inflammatory and anti-viral effects to target the complex pathophysiology of MS. As a selective immune modulator, it activates the neuroprotective transcription factor, nuclear receptor-related 1 (Nurr1), which provides direct and indirect neuroprotective effects. Additionally, vidofludimus calcium achieves anti-inflammatory and anti-viral effects through highly selective inhibition of the enzyme dihydroorotate dehydrogenase (DHODH). Vidofludimus calcium is currently being evaluated in phase 3 clinical trials for the treatment of relapsing MS. In a phase 2 clinical trial, it has shown therapeutic activity in relapsing-remitting MS patients, significantly reducing brain lesions and demonstrating encouraging results in reducing confirmed disability worsening. Additionally, vidofludimus calcium has demonstrated clinical benefits in progressive MS patients by showing substantial reductions in confirmed disability worsening and thalamic brain volume in a phase 2 clinical trial. To date, vidofludimus calcium has been exposed to approximately 2,700 individuals and has shown an attractive pharmacokinetic, safety and tolerability profile. Vidofludimus calcium is not yet licensed or approved in any country. About Immunic, Inc. (Nasdaq: IMUX) is a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammatory and autoimmune diseases. The company's lead development program, vidofludimus calcium (IMU-838), is currently in phase 3 clinical trials for the treatment of relapsing multiple sclerosis, for which top-line data is expected to be available by the end of 2026. It has already shown therapeutic activity in phase 2 clinical trials in patients suffering from relapsing-remitting multiple sclerosis and progressive multiple sclerosis. Vidofludimus calcium combines neuroprotective effects, through its mechanism as a first-in-class nuclear receptor related 1 (Nurr1) activator, with additional anti-inflammatory and anti-viral effects, by selectively inhibiting the enzyme dihydroorotate dehydrogenase (DHODH). IMU-856, which targets the protein Sirtuin 6 (SIRT6), is intended to restore intestinal barrier function and regenerate bowel epithelium, which could potentially be applicable in numerous gastrointestinal diseases, such as celiac disease as well as inflammatory bowel disease, Graft-versus-Host-Disease and weight management. IMU-381, which currently is in preclinical testing, is a next generation molecule being developed to specifically address the needs of gastrointestinal diseases. For further information, please visit: Cautionary Statement Regarding Forward-Looking StatementsThis press release contains "forward-looking statements" that involve substantial risks and uncertainties for purposes of the safe harbor provided by the Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical facts, included in this press release regarding strategy, future operations, future financial position, future revenue, projected expenses, sufficiency of cash and cash runway, expected timing, development and results of clinical trials, prospects, plans and objectives of management are forward-looking statements. Examples of such statements include, but are not limited to, statements relating to Immunic's development programs and the targeted diseases; the potential for vidofludimus calcium to safely and effectively target diseases; preclinical and clinical data for vidofludimus calcium; the feasibility of advancing vidofludimus calcium to a confirmatory phase 3 clinical trial in progressive multiple sclerosis; the timing of current and future clinical trials and anticipated clinical milestones; the nature, strategy and focus of the company and further updates with respect thereto; and the development and commercial potential of any product candidates of the company. Immunic may not actually achieve the plans, carry out the intentions or meet the expectations or projections disclosed in the forward-looking statements and you should not place undue reliance on these forward-looking statements. Such statements are based on management's current expectations and involve substantial risks and uncertainties. Actual results and performance could differ materially from those projected in the forward-looking statements as a result of many factors, including, without limitation, increasing inflation, tariffs and macroeconomics trends, impacts of the Ukraine – Russia conflict and the conflict in the Middle East on planned and ongoing clinical trials, risks and uncertainties associated with the ability to project future cash utilization and reserves needed for contingent future liabilities and business operations, the availability of sufficient financial and other resources to meet business objectives and operational requirements, the fact that the results of earlier preclinical studies and clinical trials may not be predictive of future clinical trial results, any changes to the size of the target markets for the company's products or product candidates, the protection and market exclusivity provided by Immunic's intellectual property, risks related to the drug development and the regulatory approval process and the impact of competitive products and technological changes. A further list and descriptions of these risks, uncertainties and other factors can be found in the section captioned "Risk Factors," in the company's Annual Report on Form 10-K for the fiscal year ended December 31, 2024, filed with the SEC on March 31, 2025, and in the company's subsequent filings with the SEC. Copies of these filings are available online at or Any forward-looking statement made in this release speaks only as of the date of this release. Immunic disclaims any intent or obligation to update these forward-looking statements to reflect events or circumstances that exist after the date on which they were made. Immunic expressly disclaims all liability in respect to actions taken or not taken based on any or all of the contents of this press release. Contact Information Immunic, BreuVice President Investor Relations and Communications+49 89 2080 477 US IR ContactRx Communications GroupPaula Schwartz+1 917 633 7790immunic@ US Media ContactKCSA Strategic CommunicationsCaitlin Kasunich+1 212 896 1241ckasunich@ View original content to download multimedia: SOURCE Immunic, Inc. Sign in to access your portfolio
Yahoo
8 hours ago
- Yahoo
Airworthiness Safety Conference 2025: Hear from Experts in Safety Management, Next-gen Safety, and Remote Pilot Systems (London, United Kingdom - October 21, 2025)
Join renowned speakers in London for a global event focused on aviation safety. Engage in discussions, idea sharing, and networking. Agenda highlights include airworthiness, . Elevate your aviation expertise today! Safety in Airworthiness Dublin, June 05, 2025 (GLOBE NEWSWIRE) -- The "Safety in Airworthiness" has been added to offering. Join leading experts and renowned speakers at an extraordinary global event hosted in London, dedicated to redefining aviation safety standards. This highly anticipated conference is set to become a pivotal meeting point for industry professionals passionate about enhancing safety measures and implementing innovative solutions in aviation. The conference extends a unique opportunity for participants to engage with distinguished industry leaders and fellow professionals. Attendees will benefit from an environment that fosters in-depth discussions, strategic idea sharing, and substantial networking opportunities, all aimed at advancing the collective knowledge and practice of aviation safety. The meticulously curated agenda spans a range of critical topics that are shaping the future of aviation safety: Introduction - A Regulator's view of Safety in Airworthiness: Gain insights into contemporary regulatory frameworks and their impact on safety. Safety in Part 21 - What is the Industry Seeing?: Discover current industry trends and challenges in maintaining Part 21 compliance. Measuring Safety in Continuing Airworthiness: Explore methodologies for quantifying and enhancing airworthiness in ongoing operations. Delivering the Next Generation of Safety Professionals: Discuss strategies for developing the future workforce and leadership in aviation safety. Influencing Aviation Safety Behaviours and Promoting Wellbeing: Examine approaches to fostering a safety-oriented culture and prioritizing well-being. Worldwide Safety Management Systems Issues, and How to Solve Them: Address global Safety Management System challenges and innovative solutions. Remote Pilot Air Systems - Beyond Visual Line of Sight Operations: Investigate advancements and regulatory considerations for remote piloting beyond visual range. Agenda: 8.45 - Registration & Networking Coffee 9.15 - Opening RemarksPanagiotis Panagopoulos, CEO & Founder, AeropodiumIan Dearing, Chief Surveyor - Airworthiness, 2-REG Aircraft Registry 9.45 - Introduction - A Regulator's View of Safety in AirworthinessIan Dearing, Chief Surveyor - Airworthiness, 2-REG Aircraft Registry 10.15 - Safety in Part 21 - What is the Industry Seeing?Jack Coleman, Initial Airworthiness, Independent Consultant 10.45 - Measuring Safety in Continuing AirworthinessPaul White, Continuing Airworthiness, Independent Consultant 11.15 - Networking Coffee Break 11.45 - Delivering the Next Generation of Safety ProfessionalsNicola Osborne, Director Safety & Compliance, Titan Airways 12.15 - Influencing Aviation Safety Behaviours and Promoting WellbeingSam Lee, Managing Director, Integra Aerospace 12.45 - Networking Lunch Break 13.45 - Worldwide Safety Management Systems Issues, and How to Solve ThemSilas Hays, Safety Management, Independent Consultant 14.30 - Remote Pilot Air Systems - Beyond Visual Line of Sight OperationsBecky Smith, Continuing Airworthiness Manager, National Grid 15.00 - Networking Coffee Break 15.30 - Speakers' Panel Q&A 16.30 - Concluding Remarks Speakers Jack Coleman, Initial Airworthiness, Independent Consultant Ian Dearing, Chief Surveyor - Airworthiness, 2-REG Aircraft Registry Silas Hays, Safety Management, Independent Consultant Sam Lee, Managing Director, Integra Aerospace Nicola Osborne, Director Safety & Compliance, Titan Airways Becky Smith, Continuing Airworthiness Manager, National Grid Paul White, Continuing Airworthiness, Independent Consultant For more information about this conference visit About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. Attachment Safety in Airworthiness CONTACT: CONTACT: Laura Wood,Senior Press Manager press@ For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900Sign in to access your portfolio